Jasper Therapeutics, Inc. (JSPR)
NCM · Healthcare · Biotechnology
$0.46
-1.72%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$12.8M
Shares Outstanding
28.0M
Exchange
NCM
Currency
USD
About Jasper Therapeutics, Inc.
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma. Jasper Therapeutics, Inc. was founded in 2018 and is headquartered in Redwood City, California.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -27.1M | -19.2M | -15.8M | -11.0M |
| Net Income | -26.7M | -18.7M | -9.1M | -1.2M |
| Diluted EPS | $-1.74 | $-1.13 | $-0.32 | $-0.04 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -51.2M | -68.9M | -76.2M | -83.9M |
| Net Income | -37.7M | -64.5M | -71.3M | -75.8M |
| Diluted EPS | $-10.30 | $-6.18 | $-4.89 | $-3.95 |